Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer.
Abstract | UNLABELLED: BACKGROUND: MATERIALS AND METHODS: We determined the activation of these pathways (phosphorylated MAPK [pMAPK] and protein S6 [pS6; a downstream molecule of PI3K/Akt/ mammalian target of rapamycin (mTOR)/ S6 kinase (S6K)]) in 108 ER(+), HER2(-) breast cancer cases with high and low Ki-67 expression. The ER, progesterone receptor (PgR), Ki-67, p53 expression levels were also determined immunohistochemically. The cutoff value for Ki-67 was set at 15%. RESULTS: A significantly greater percentage of cancer cases with high Ki-67 expression showed pS6 positivity than did those with low Ki-67 expression (53.2% vs. 19.7%; P = .0003). No significant differences were found between the cases with high and low expression levels were detected for p53 (23.4% vs. 11.5%; P = .12) or pMAPK (36.2% vs. 34.4%; P = .85) positivity. Multivariate analysis showed that pS6 positivity (odds ratio 5.16, 95% confidence interval 1.95-13.63; P = .0009), nuclear grade 2 and 3, and low PgR expression (≤ 20%) were independently associated with the high Ki-67 subset. CONCLUSION: From our findings, we have concluded that the pS6 expression level is associated with the characteristics of breast cancer with high Ki-67 expression. Because these associations were observed, irrespective of menopausal status, the biologic difference seems to be less affected by estrogen signaling than by activation of S6 protein, especially in terms of proliferation. Our findings have also indicated that targeting the mTOR/S6K pathway might be a useful strategy for the treatment of ER(+)/HER2(-) breast cancer with high Ki-67 expression.
|
Authors | Ayako Yanai, Natsuko Inoue, Tomoko Yagi, Arisa Nishimukai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Yukie Enomoto, Yuichi Takatsuka, Takahiro Watanabe, Seiichi Hirota, Mitsunori Sasa, Toyomasa Katagiri, Yasuo Miyoshi |
Journal | Clinical breast cancer
(Clin Breast Cancer)
Vol. 15
Issue 3
Pg. 197-203
(Jun 2015)
ISSN: 1938-0666 [Electronic] United States |
PMID | 25600244
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- Ki-67 Antigen
- Receptors, Estrogen
- MTOR protein, human
- ERBB2 protein, human
- Receptor, ErbB-2
- Ribosomal Protein S6 Kinases
- TOR Serine-Threonine Kinases
- Mitogen-Activated Protein Kinases
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Breast Neoplasms
(metabolism, pathology, surgery)
- Carcinoma, Ductal, Breast
(metabolism, pathology, surgery)
- Carcinoma, Lobular
(metabolism, pathology, surgery)
- Female
- Humans
- Ki-67 Antigen
(biosynthesis)
- Middle Aged
- Mitogen-Activated Protein Kinases
(metabolism)
- Phosphatidylinositol 3-Kinases
(metabolism)
- Phosphorylation
- Receptor, ErbB-2
(metabolism)
- Receptors, Estrogen
(metabolism)
- Ribosomal Protein S6 Kinases
(biosynthesis, metabolism)
- Signal Transduction
- TOR Serine-Threonine Kinases
(metabolism)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|